Kiniksa Pharmaceuticals International SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 27, 2026, 7:32 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedKiniksa Pharmaceuticals Q3 2026 revenue of $286.0 million beats $260.6 million consensus, and ARCALYST 2026 guidance is raised to $1.045-$1.050 billion
10-QOct. 27, 2026, 4:36 p.m. ETView on SEC.gov
8-KOct. 22, 2026, 4:28 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
AI summary, unreviewedKiniksa Pharmaceuticals promotes EVP and COO Ross Moat to President and Chief Operating Officer, with base salary raised to $700,000 and target bonus to 60%
4Sept. 3, 2026, 4:41 p.m. ETView on SEC.gov
4Sept. 3, 2026, 4:49 p.m. ETView on SEC.gov
4Sept. 3, 2026, 4:43 p.m. ETView on SEC.gov
4Sept. 3, 2026, 4:48 p.m. ETView on SEC.gov
4Sept. 3, 2026, 4:46 p.m. ETView on SEC.gov
4Sept. 3, 2026, 4:40 p.m. ETView on SEC.gov
4Aug. 21, 2026, 4:35 p.m. ETView on SEC.gov
4Aug. 4, 2026, 4:40 p.m. ETView on SEC.gov
4July 31, 2026, 4:34 p.m. ETView on SEC.gov
SCHEDULE 13GJuly 29, 2026, 3:19 p.m. ETView on SEC.gov
8-KJuly 28, 2026, 7:33 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
10-QJuly 28, 2026, 4:17 p.m. ETView on SEC.gov